Suary DNA from 67 primary breast carcinoma biopsies has been examined for loss of heterozygosity (LOH) using the microsatellite (TA), repeat marker positioned 1 kb upstream of the oestrogen receptor (ER) gene. Forty-seven (70.1%) of the cases were informative; nine of these (19.1%) were positive for LOH. In three of the nine cases, there was total loss, and in the other six cases there was a marked reduction in thintensity of signal from one allele. LOH correlated weakly with histological grade and age, but not with ER status. This result suggests that LOH of the ER gene does not have an imnportant role in the lack of ER function in breast cancer tissues.
Human breast cancer is one of the typical hormone-dependent tumours, and approximately one-third of breast cancer patients respond to endocrine therapy (Rubens et al., 1980) . The oestrogen receptor (ER) is a 66 kDa intranuclear protein consisting of six functional domains and is a ligand-activated transcription factor (Ponglilitmongkol et al., 1988) . Cur- rently, ER content in tumours is not used to predict those patients who might benefit from endocrine therapy. ER status also provides prognostic information (Stewart et al., 1982) . Tumours lacking ER and progesterone receptor (PgR) generally grow faster than tumours containing both ER and PgR (McGuire and Clark, 1989) .
Genetic alterations are believed to play an important role in the origin and dissemination of breast cancer (Sato et al., 1991) . Frequent loss of heterozygosity (LOH) in breast tumour DNA, which implies the presence of a tumour-suppressor gene, has been detected on chromosomes lq, 3p, 6q, 7q, lIp, 13q, 16q, 17p, 17q and 18q (Devilee et al., 1991; Pathak et al., 1991; Sato et al., 1991; Thorlacius et al., 1991; Andersen et al., 1992; Bieche et al., 1992; Knyazev et al., 1993) . The ER gene is located on chromosome 6q25.1 (Menasce et al., 1993) , and its total size, including introns, is about 140kb (Ponglikitmongkol et al., 1988) . LOH at the ER locus on chromosome 6q has previously been reported in human ovarian carcinomas (Lee et al., 1990) and in human breast cancer (Devilee et al., 1991) .
In this report, we examined LOH on the ER gene in 67 breast cancer patients using a highly informative microsatellite TA repeat marker positioned 1 kb upstream of the ER gene (Senno et al., 1992 (WHO, 1981) . Patients were graded histopathologically according to the modified Bloom and Richardson method of Elston and Ellis, (1991) . Blood samples also were taken from each patient. Genomic DNA from the breast cancer specimens and the blood samples was extracted by standard techniques (Sambrook et al., 1989) .
Oestrogen and progesterone receptor determinations Cytosolic ER and PgR levels were measured using enzyme immunoassay (ER-and PgR-EIA, Abbott Laboratories, Chicago, IL, USA). Positive ER and PgR status was defined as more than 20 fmol mg'-protein.
Microsatellite (TA), repeat polymorphism The polymorphic (TA),, repeat (Weissenbach, 1993) was identified in the upstream region of the human ER gene (Senno et al., 1992) . Polymerase chain reaction (PCR) assays (Saiki et al., 1985) were performed using 32P-labelled primers in 25 IlI of a buffer containing 1.5 mM magnesium chloride, 0.5mM DNTPS and 50-lOOng of human tumour or blood DNA. PCR primers were: ER-1, 5'-GACGCATGATATACT-TCACC-3' (TA strand); and ER-2, 5'-GCAGAATCAAAT-ATCCAGATG-3' (AT strand). Amplification conditions were as follows: denaturation for 5 min at 94°C: followed by 19 cycles at 94°C for 1 min, 58°C for 1 min, 72'C for 1.5 min and a final extension at 72°C for 5 min. The PCR products were separated by electrophoresis on a 5% denaturing polyacrylamide gel, and alleles were detected by autoradiography.
Statistical analvsis
All comparisons between LOH and clinicopathological parameters were performed using the Kendall test. P-values <0.05 were considered statistically significant.
Results

Loss of heterozygositv of the ER gene
The DNAs from a total of 67 tumours were studied for allele loss using the dinucleotide TA repeat microsatellite marker, positioned just upstream of the ER gene. Constitutional heterozygosity was observed in 47 cases (70.1%), and, of these, clear LOH was seen in nine (19.1%) (Figure 1) Figure 2 shows a quantitative assessment of ER value vs LOH of the ER gene and demonstrates that there was no relationship between them.
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In the early stages of human breast cancer the proliferation of tumour cells depends on oestrogen. After that, the cancer cells may acquire new proliferative pathways sequentially as a result of multiple genetic alterations. This then enables the tumour cells to bypass the oestrogen-dependent proliferation (Liu et at., 1988) . Although there are many reports concerning variant ER genes (Sluyser, 1992; Fuqua et al., 1993; Pfeffer et at., 1993) , the reason for the existence of ERnegative breast cancer is still not understood. (1991) reported that the frequency of LOH on 6q was as high as 50%, and also found no relationship between LOH on 6q and ER status using the markers D6S37 and MYB (locus 6q27 and 6q22-q23 respectively).
On the other hand, it is possible for LOH to be randomly acquired and irrelevant to tumour development (Chen et al., 1992) . The background incidence of random allelic losses may be higher in later stage lesions because they have had a longer time for randomly acquired lesions to be co-selected with other mutations which confer a selective advantage associated with malignant progression. The frequency of background LOH has been reported as 4-15% (Sato et al., 1990; Chen et al., 1992) . In our case, the incidence of LOH on the ER gene might be higher than the background LOH.
In summary, we found no relationship between LOH on the ER gene and the lack of ER function in breast cancer tissue. Further molecular investigation is therefore required to understand the molecular basis of ER-negative breast cancer.
